leucovorin rescue

leucovorin rescue

Oncology A strategy–administration of a formulation of vitamin B for preventing 'collateral damage' to normal cells when using MTX, an antimetabolite, to treat lymphomas and other malignancies, which may cause BM suppression and GI Sx. See Methotrexate.
References in periodicals archive ?
sup][2] Hydration, alkalinization, and leucovorin rescue have evolved to routine clinical administration since Jaffe started to use HD-MTX to treat osteosarcoma in 1972,[sup][3] but delayed excretion of methotrexate (MTX) can occur to cause gastrointestinal reactions, oral mucositis, increases in levels of liver enzymes, neurotoxicity, and hematologic toxicity.
After completion of MTX infusion for 6–8 h, leucovorin rescue (12 mg, q6h) is started until the serum concentration of MTX falls to 0.
HD-MTX with leucovorin rescue is used to treat osteosarcoma (8-12 jers [m.
Carboxypeptidase-G2, thymidine and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
He received 4 cycles of high-dose methotrexate (HDMTX) [3] with leucovorin rescue and 2 cycles of cisplatin and doxorubicin, which he tolerated well.
Because MTX and creatinine concentrations were decreasing steadily, the decision was made to complete intravenous hydration at 170 mL/h and leucovorin rescue with 250 mg administered intravenously every 6 h at home until the MTX concentration was < 0.
She underwent leucovorin rescue as the thrombocytopenia was felt to be due to the methotrexate.
Treatment with intravenous HD-MTX and calcium leucovorin rescue was begun.
Calcium leucovorin rescue is administered 24 hours after the start of the MTX administration.
The incidence of toxicity has decreased as a result of plasma MTX concentration monitoring and appropriate leucovorin rescue, combined with adequate hydration and urine alkalinization.
The pediatric ALL community remains divided concerning the use of either "industrial" MTX doses with leucovorin rescue [Berlin-Frankfurt-Munster Cooperative Group (BFM) (15), United Kingdom ALL Cooperative Group (UKALL) (1), and Nordic (10) studies] or repeated, escalating low doses of systemic MTX administered with absolutely no leucovorin rescue, the so-called Capizzi methotrexate (5, 16), which also has apparent clinical efficacy (17, 18).
The resulting delayed MTX elimination can exacerbate other MTX toxicities because leucovorin rescue is less effective with persistently increased MTX concentrations.